Banner

Basal insulin plus pramlintide at mealtime controls glucose, with lower hypoglycemia risk

Article

Pramlintide injection added to basal insulin at mealtime is similar to titrated rapid-acting insulin in achieving glycemic control but with a lower risk of hypoglycemia and no weight gain in patients with type 2 diabetes, said Matthew Riddle, MD, head, section of diabetes, division of endocrinology/diabetes/clinical nutrition, Oregon Health and Sciences University, Portland.

Pramlintide injection added to basal insulin at mealtime is similar to titrated rapid-acting insulin in achieving glycemic control but with a lower risk of hypoglycemia and no weight gain in patients with type 2 diabetes, said Matthew Riddle, MD, head, section of diabetes, division of endocrinology/diabetes/clinical nutrition, Oregon Health and Sciences University, Portland.

"Beginning mealtime treatment with pramlintide could be a preferable potential alternative to rapid-acting insulin for many patients," he said.

The two strategies were compared in an open-label, 24-week, multicenter study of 112 patients who were either insulin-naive or taking less than 50 units of daily of insulin for less than 6 months. To be included, patients had to have a hemoglobin A1c of 7 to 10% and could be taking any combination of metformin, a sulfonylurea, and a thiazolidinedione.

The mean body mass index at baseline was 36 kg/m2. Almost half the patients had used insulin previously.

Basal insulin was titrated in both groups to achieve a fasting plasma glucose levels of 70 to <100 mg/dL. A fixed 120-mcg dose of pramlintide was started on day 1; in the other treatment group, rapid-acting insulin was started at week 4 to allow titration of the initial basal insulin dose to reduce the risk of mealtime insulin-induced hypoglycemia.

At 24 weeks, the reductions in A1c levels from baseline were similar with the two strategies (0.9% in the pramlintide-treated patients versus 1.1% in the group receiving rapid-acting insulin). Final fasting plasma glucose levels were also similar in the pramlintide and rapid-acting insulin groups (122 mg/dL vs. 123 mg/dL, respectively).

Patients treated with rapid-acting insulin gained a mean of 6.2 kg of body weight whereas those treated with pramlintide had a reduction in body weight of 0.3 kg (p < 0.0001 versus rapid-acting insulin).

Fifty-five percent of the pramlintide group experienced a hypoglycemic episode compared with 82% of those treated with rapid-acting insulin; there were no severe hypoglycemic events reported.

The primary composite endpoint of an A1c level ≤7.0% with no increase in body weight and no severe hypoglycemia was achieved by 30% of pramlintide recipients versus 11% of patients taking rapid-acting insulin (p < 0.05).

Twenty-one percent of patients in the pramlintide group had nausea compared with 0% of the group taking rapid-acting insulin. Nausea in the pramlintide group was mostly mild to moderate in severity; only one case was reported during the last 6 weeks of the study. There were two subjects in the pramlintide group who dropped out of the study because of nausea. The total dropout rates were 14% in the pramlintide group and 11% in the group taking rapid-acting insulin.

Related Videos
Robert E. Oshel, PhD
Robert E. Oshel, PhD
Robert E. Oshel, PhD
Gary Price, MD, MBA
Gary Price, MD, MBA
Gary Price, MD, MBA
Gary Price, MD, MBA
Gary Price, MD, MBA
Gary Price, MD, MBA
Gary Price, MD, MBA
© 2023 MJH Life Sciences

All rights reserved.